Cargando…

Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal?

Localized cutaneous leishmaniasis caused by Leishmania braziliensis can either respond well or poorly to the treatment or heal spontaneously; It seems to be dependent on the parasite and/or host factors, but the mechanisms are not fully understood. We evaluated the in situ immune response in eighty-...

Descripción completa

Detalles Bibliográficos
Autores principales: Leite-Silva, Jéssica, Oliveira-Ribeiro, Carla, Morgado, Fernanda Nazaré, Pimentel, Maria Inês Fernandes, Lyra, Marcelo Rosandiski, Fagundes, Aline, Miranda, Luciana Freitas Campos, Valete-Rosalino, Claudia Maria, Schubach, Armando Oliveira, Conceição-Silva, Fátima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384164/
https://www.ncbi.nlm.nih.gov/pubmed/37512804
http://dx.doi.org/10.3390/microorganisms11071631
_version_ 1785081090011037696
author Leite-Silva, Jéssica
Oliveira-Ribeiro, Carla
Morgado, Fernanda Nazaré
Pimentel, Maria Inês Fernandes
Lyra, Marcelo Rosandiski
Fagundes, Aline
Miranda, Luciana Freitas Campos
Valete-Rosalino, Claudia Maria
Schubach, Armando Oliveira
Conceição-Silva, Fátima
author_facet Leite-Silva, Jéssica
Oliveira-Ribeiro, Carla
Morgado, Fernanda Nazaré
Pimentel, Maria Inês Fernandes
Lyra, Marcelo Rosandiski
Fagundes, Aline
Miranda, Luciana Freitas Campos
Valete-Rosalino, Claudia Maria
Schubach, Armando Oliveira
Conceição-Silva, Fátima
author_sort Leite-Silva, Jéssica
collection PubMed
description Localized cutaneous leishmaniasis caused by Leishmania braziliensis can either respond well or poorly to the treatment or heal spontaneously; It seems to be dependent on the parasite and/or host factors, but the mechanisms are not fully understood. We evaluated the in situ immune response in eighty-two active lesions from fifty-eight patients prior to treatment classified as early spontaneous regression (SRL-n = 14); treatment responders (GRL-n = 20); and non-responders (before first treatment/relapse, PRL1/PRL2-n = 24 each). Immunohistochemistry was used to identify cell/functional markers which were correlated with the clinical characteristics. PRL showed significant differences in lesion number/size, clinical evolution, and positive parasitological examinations when compared with the other groups. SRL presented a more efficient immune response than GRL and PRL, with higher IFN-γ/NOS2 and a lower percentage of macrophages, neutrophils, NK, B cells, and Ki-67+ cells. Compared to SRL, PRL had fewer CD4+ Tcells and more CD163+ macrophages. PRL1 had more CD68+ macrophages and Ki-67+ cells but less IFN-γ than GRL. PRL present a less efficient immune profile, which could explain the poor treatment response, while SRL had a more balanced immune response profile for lesion healing. Altogether, these evaluations suggest a differentiated profile of the organization of the inflammatory process for lesions of different tegumentary leishmaniasis evolution.
format Online
Article
Text
id pubmed-10384164
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103841642023-07-30 Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal? Leite-Silva, Jéssica Oliveira-Ribeiro, Carla Morgado, Fernanda Nazaré Pimentel, Maria Inês Fernandes Lyra, Marcelo Rosandiski Fagundes, Aline Miranda, Luciana Freitas Campos Valete-Rosalino, Claudia Maria Schubach, Armando Oliveira Conceição-Silva, Fátima Microorganisms Article Localized cutaneous leishmaniasis caused by Leishmania braziliensis can either respond well or poorly to the treatment or heal spontaneously; It seems to be dependent on the parasite and/or host factors, but the mechanisms are not fully understood. We evaluated the in situ immune response in eighty-two active lesions from fifty-eight patients prior to treatment classified as early spontaneous regression (SRL-n = 14); treatment responders (GRL-n = 20); and non-responders (before first treatment/relapse, PRL1/PRL2-n = 24 each). Immunohistochemistry was used to identify cell/functional markers which were correlated with the clinical characteristics. PRL showed significant differences in lesion number/size, clinical evolution, and positive parasitological examinations when compared with the other groups. SRL presented a more efficient immune response than GRL and PRL, with higher IFN-γ/NOS2 and a lower percentage of macrophages, neutrophils, NK, B cells, and Ki-67+ cells. Compared to SRL, PRL had fewer CD4+ Tcells and more CD163+ macrophages. PRL1 had more CD68+ macrophages and Ki-67+ cells but less IFN-γ than GRL. PRL present a less efficient immune profile, which could explain the poor treatment response, while SRL had a more balanced immune response profile for lesion healing. Altogether, these evaluations suggest a differentiated profile of the organization of the inflammatory process for lesions of different tegumentary leishmaniasis evolution. MDPI 2023-06-22 /pmc/articles/PMC10384164/ /pubmed/37512804 http://dx.doi.org/10.3390/microorganisms11071631 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Leite-Silva, Jéssica
Oliveira-Ribeiro, Carla
Morgado, Fernanda Nazaré
Pimentel, Maria Inês Fernandes
Lyra, Marcelo Rosandiski
Fagundes, Aline
Miranda, Luciana Freitas Campos
Valete-Rosalino, Claudia Maria
Schubach, Armando Oliveira
Conceição-Silva, Fátima
Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal?
title Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal?
title_full Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal?
title_fullStr Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal?
title_full_unstemmed Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal?
title_short Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal?
title_sort is there any difference in the in situ immune response in active localized cutaneous leishmaniasis that respond well or poorly to meglumine antimoniate treatment or spontaneously heal?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384164/
https://www.ncbi.nlm.nih.gov/pubmed/37512804
http://dx.doi.org/10.3390/microorganisms11071631
work_keys_str_mv AT leitesilvajessica isthereanydifferenceintheinsituimmuneresponseinactivelocalizedcutaneousleishmaniasisthatrespondwellorpoorlytomeglumineantimoniatetreatmentorspontaneouslyheal
AT oliveiraribeirocarla isthereanydifferenceintheinsituimmuneresponseinactivelocalizedcutaneousleishmaniasisthatrespondwellorpoorlytomeglumineantimoniatetreatmentorspontaneouslyheal
AT morgadofernandanazare isthereanydifferenceintheinsituimmuneresponseinactivelocalizedcutaneousleishmaniasisthatrespondwellorpoorlytomeglumineantimoniatetreatmentorspontaneouslyheal
AT pimentelmariainesfernandes isthereanydifferenceintheinsituimmuneresponseinactivelocalizedcutaneousleishmaniasisthatrespondwellorpoorlytomeglumineantimoniatetreatmentorspontaneouslyheal
AT lyramarcelorosandiski isthereanydifferenceintheinsituimmuneresponseinactivelocalizedcutaneousleishmaniasisthatrespondwellorpoorlytomeglumineantimoniatetreatmentorspontaneouslyheal
AT fagundesaline isthereanydifferenceintheinsituimmuneresponseinactivelocalizedcutaneousleishmaniasisthatrespondwellorpoorlytomeglumineantimoniatetreatmentorspontaneouslyheal
AT mirandalucianafreitascampos isthereanydifferenceintheinsituimmuneresponseinactivelocalizedcutaneousleishmaniasisthatrespondwellorpoorlytomeglumineantimoniatetreatmentorspontaneouslyheal
AT valeterosalinoclaudiamaria isthereanydifferenceintheinsituimmuneresponseinactivelocalizedcutaneousleishmaniasisthatrespondwellorpoorlytomeglumineantimoniatetreatmentorspontaneouslyheal
AT schubacharmandooliveira isthereanydifferenceintheinsituimmuneresponseinactivelocalizedcutaneousleishmaniasisthatrespondwellorpoorlytomeglumineantimoniatetreatmentorspontaneouslyheal
AT conceicaosilvafatima isthereanydifferenceintheinsituimmuneresponseinactivelocalizedcutaneousleishmaniasisthatrespondwellorpoorlytomeglumineantimoniatetreatmentorspontaneouslyheal